(24/7 MARKET NEWS) – NanoVibronix, Inc. (NAOV:NASDAQ) cited, this morning, positive reported outcomes from a study of UroShield conducted at the University of Southampton in the United Kingdom.
Brian Murphy, NanoVibronix CEO, said, “As the researchers at Southampton point out, incidences of catheter-associated urinary tract infections (CAUTI) continue to be a major clinical concern, with serious implications for patients and considerable impact on healthcare facilities and resources. We are pleased to learn that through an independent study, researchers witnessed positive outcomes from the use of UroShield both in the lab and with patients. Quantitative data from the research indicated a positive effect of UroShield on catheter-associated urinary tract infections (CAUTI) and catheter blockage with approximately one-third of patients in the study citing a reduction in the frequency of catheter blockages and the need for unscheduled catheter challenges. Furthermore, qualitative data indicated favorable opinions from the majority of the participants and confirmation that the Uroshield was having a positive effect.”
NanoVibronix is trading at $1.83, up $0.36 (+24.49%), on 653.31K premarket shares traded.
Its 52-week range is $1.41 to $12.90. If it breaks through the resistance in the low twos, it should, at least, make a run at the $2.75 inflection point and, if the trading volume strengthens, it may do more.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
